Bayer starts legal proceedings in Russia due to violation of IP rights

7 February 2018

Germany’s Bayer (BAYN: DE) has started legal proceedings in Russia, filling a lawsuit against a local drugmaker Nativa, which registered a generic of Bayer’s anticancer drug prior to the expiration of the patent for the original drug, according to representatives of the German company.

The subject of the lawsuit is Bayer’s Nexavar, as well as its active substance sorafenib, reports The Pharma Letter’s local correspondent. The terms of their patents due to expire in 2022 and 2026 respectively.

In its lawsuit Bayer asks the Arbitration Court of the Moscow region to impose a ban on the production and sales of the generic, produced by Nativa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK